Long-term prognostic value of lowering in free triiodothyronine in patients with hypertrophic cardiomyopathy
10.3760/cma.j.issn.0578-1426.2018.04.006
- VernacularTitle:游离三碘甲状腺原氨酸降低对肥厚型心肌病患者远期预后的影响
- Author:
Xiangbin MENG
1
,
2
;
Wenyao WANG
;
Kuo ZHANG
;
Yu QI
;
Shimin AN
;
Siyuan WANG
;
Jilin ZHENG
;
Qinjun YU
;
Bing TANG
;
Rong WU
;
Chuanyu GAO
;
Shuiyun WANG
;
Yida TANG
Author Information
1. 100037 中国医学科学院北京协和医学院国家心血管病中心心血管疾病国家重点实验室阜外医院心血管内科
2. 郑州大学人民医院心血管内科
- Keywords:
Triiodothyronine;
Cardiomyopathy,hypertrophic;
Prognosis
- From:
Chinese Journal of Internal Medicine
2018;57(4):258-263
- CountryChina
- Language:Chinese
-
Abstract:
Objective To determine whether thyroid hormone (TH) level could also be an independent and incremental predictor of adverse events in patients with hypertrophic cardiomyopathy (HCM).Methods A total of 982 consecutive patients with HCM at the National Center for Cardiovascular Diseases (China) from October 2009 to December 2013 were included in the present study,and followed up till the end of December 2016.The patients were divided into three groups according to the levels of free triiodothyronine (FT3):the group 1 (FT3≤4.28 pmol/L,n=335),the group 2 (FT3＞4.28-＜4.79 pmol/L,n=310),and the group 3 (FT34.79-6.30 pmol/L,n=337).Results After a follow-up period of (53.8 ± 14.1) months,39 patients (4.0％) either suffered death with all causes or received a cardiac transplantation (7.8％,2.9％ and 1.2％ of the patients in the group 1,group 2 and group 3,respectively).A multivariable Cox regression analysis revealed that FT3≤4.28 pmol/L was associated with a significantly higher risk of all-cause mortality or cardiac transplantation (HR 8.83,95％ CI 1.115-69.905,P=0.039) in HCM patients.Conclusions Low levels of FT3 is a risk factor of adverse events for patients with HCM,indicting a role of FT3 as a marker for assessing the risk of long-term adverse events in these patients.
